Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Chee-Shee Chai,1 Chong-Kin Liam,2 Mau-Ern Poh,2 Diana Bee-Lan Ong,3 Yong-Kek Pang,2 Phaik-Leng Cheah,3 Gwo-Fuang Ho,4 Adlinda Alip4 1Department of Medicine, Faculty of Medicine and Health Science, University Malaysia Sarawak, Kota Samarahan, Sarawak, Malaysia; 2Department of Medicine, Faculty of Med...

Full description

Bibliographic Details
Main Authors:	Chai CS, Liam CK, Poh ME, Ong DBL, Pang YK, Cheah PL, Ho GF, Alip A
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-07-01
Series:	Cancer Management and Research
Subjects:	non-small cell lung cancer epidermal growth factor receptor acquired t790m mutation independent predictor tyrosine kinase inhibitor.
Online Access:	https://www.dovepress.com/predictors-of-acquired-t790m-mutation-in-patients-failing-first--or-se-peer-reviewed-article-CMAR

Similar Items

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
by: Zhang H
Published: (2016-11-01)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
by: Nobuaki Kobayashi, et al.
Published: (2021-04-01)

T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors
by: Vinodini Merinda, et al.
Published: (2020-01-01)

TKI Resistance for T790M Mutation
by: Hong WANG, et al.
Published: (2015-04-01)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
by: Tristan A. Barnes, et al.
Published: (2017-05-01)

A case with psoriasis-like lesions induced by olmutinib (HM61713) while treating epidermal growth factor receptor T790M mutant advanced lung adenocarcinoma
by: Chu-Ju Hung, et al.
Published: (2019-01-01)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018-08-01)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021-03-01)

EGFR T790M: revealing the secrets of a gatekeeper
by: Ko B, et al.
Published: (2017-10-01)

Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review
by: Takuma Imakita, et al.
Published: (2019-01-01)

Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation
by: Xin WANG, et al.
Published: (2019-05-01)

Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
by: Venkata Pradeep Babu Koyyala, et al.
Published: (2018-01-01)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01)

Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study
by: Shirong Zhang, et al.
Published: (2018-05-01)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
by: E. V. Karabina, et al.
Published: (2018-11-01)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
by: Gao W, et al.
Published: (2019-11-01)

Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
by: Toshiyuki Sumi, et al.
Published: (2021-06-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
by: Tadashi Nishimura, et al.
Published: (2021-04-01)

Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma
by: Takayuki Kishikawa, et al.
Published: (2020-04-01)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
by: Shinichi Miyazaki, et al.
Published: (2020-08-01)

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in <i>EGFR</i> Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study
by: Giannis Mountzios, et al.
Published: (2021-06-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-08-01)

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
by: Liu Y, et al.
Published: (2017-04-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)

Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
by: Minehiko Inomata, et al.
Published: (2020-11-01)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
by: Lee CS, et al.
Published: (2020-10-01)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Katsuhiro Masago, et al.
Published: (2018-01-01)

Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities
by: Philomena Charlotte Dsouza, et al.
Published: (2017-01-01)

Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
by: Asao Sakai, et al.
Published: (2013-01-01)

Advanced Research on T790M Mutation in Non-small Cell Lung Cancer
by: Hui LI, et al.
Published: (2013-06-01)

Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy
by: Sahrun Sahrun, et al.
Published: (2019-10-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
by: Chia-Yu Chu, et al.
Published: (2017-06-01)

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
by: Zhang Lingling, et al.
Published: (2016-01-01)

Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
by: Fan L, et al.
Published: (2017-01-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)